FR23C1029I1 - Compositions d'anticorps anti-ctla-4 - Google Patents

Compositions d'anticorps anti-ctla-4

Info

Publication number: FR23C1029I1
Authority: FR; France
Prior art keywords: ctla; antibody compositions; antibody; compositions
Prior art date: 2005-03-08
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Active

Application number

FR23C1029C

Other languages

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Pfizer Products Inc

Original Assignee

Pfizer Products Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-03-08

Filing date

2023-07-28

Publication date

2023-10-06

2023-07-28 Application filed by Pfizer Products Inc filed Critical Pfizer Products Inc

2023-10-06 Publication of FR23C1029I1 publication Critical patent/FR23C1029I1/fr

2024-06-14 Application granted granted Critical

2024-06-14 Publication of FR23C1029I2 publication Critical patent/FR23C1029I2/fr

Status Active legal-status Critical Current

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/243—Colony Stimulating Factors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Immunology (AREA)
Epidemiology (AREA)
Diabetes (AREA)
Physical Education & Sports Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Endocrinology (AREA)
Oncology (AREA)
Pulmonology (AREA)
Mycology (AREA)
Microbiology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Rheumatology (AREA)
Hematology (AREA)
Biochemistry (AREA)
Oil, Petroleum & Natural Gas (AREA)
Communicable Diseases (AREA)
Neurology (AREA)
Dermatology (AREA)
Virology (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Nutrition Science (AREA)
Urology & Nephrology (AREA)
Obesity (AREA)

FR23C1029C 2005-03-08 2023-07-28 Compositions d'anticorps anti-ctla-4 Active FR23C1029I2 (fr)

Applications Claiming Priority (6)

Application Number	Priority Date	Filing Date	Title
US65976605P	2005-03-08	2005-03-08
US72816505P	2005-10-19	2005-10-19
US75271205P	2005-12-20	2005-12-20
US76245606P	2006-01-26	2006-01-26
PCT/US2006/007555 WO2006096491A2 (fr)	2005-03-08	2006-03-02	Compositions d'anticorps anti-ctla-4
EP06736812.6A EP1865986B1 (fr)	2005-03-08	2006-03-02	Compositions d'anticorps anti-ctla-4

Publications (2)

Publication Number	Publication Date
FR23C1029I1 true FR23C1029I1 (fr)	2023-10-06
FR23C1029I2 FR23C1029I2 (fr)	2024-06-14

Family

ID=36646098

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
FR23C1029C Active FR23C1029I2 (fr)	2005-03-08	2023-07-28	Compositions d'anticorps anti-ctla-4

Country Status (26)

Country	Link
US (5)	US20080248047A1 (fr)
EP (6)	EP2311491A1 (fr)
JP (7)	JP2006249084A (fr)
KR (2)	KR100996801B1 (fr)
CN (1)	CN103861102A (fr)
AR (4)	AR053026A1 (fr)
AU (2)	AU2006220828A1 (fr)
BR (2)	BRPI0608815B1 (fr)
CA (4)	CA2600434C (fr)
CY (2)	CY1121254T1 (fr)
DK (2)	DK2620450T3 (fr)
ES (2)	ES2707284T3 (fr)
FI (1)	FIC20230027I1 (fr)
FR (1)	FR23C1029I2 (fr)
HU (3)	HUE028410T2 (fr)
IL (3)	IL185380A0 (fr)
LT (2)	LT2620450T (fr)
LU (1)	LUC00312I2 (fr)
MX (2)	MX2007010971A (fr)
NL (1)	NL301240I2 (fr)
NZ (2)	NZ560844A (fr)
PL (1)	PL2620450T3 (fr)
PT (1)	PT2620450T (fr)
SI (2)	SI2620450T1 (fr)
TW (4)	TW200642694A (fr)
WO (4)	WO2006096490A2 (fr)

Families Citing this family (124)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2949290B2 (ja)	1989-07-26	1999-09-13	京セラ株式会社	アモルファスシリコン系半導体膜の製法
AR045563A1 (es)	2003-09-10	2005-11-02	Warner Lambert Co	Anticuerpos dirigidos a m-csf
EP1709080B1 (fr)	2004-01-09	2011-03-09	Pfizer Inc.	ANTICORPS A MAdCAM
KR100996801B1 (ko) *	2005-03-08	2010-11-25	파마시아 앤드 업존 캄파니 엘엘씨	항-ＭＡｄＣＡＭ 항체 조성물
AU2006283560B2 (en) *	2005-08-19	2011-12-08	Centocor, Inc.	Proteolysis resistant antibody preparations
CL2007002567A1 (es)	2006-09-08	2008-02-01	Amgen Inc	Proteinas aisladas de enlace a activina a humana.
AR063086A1 (es) *	2006-10-02	2008-12-23	Medarex Inc	Anticuerpos humanos que se unen a cxcr4 y usos de los mismos
US20080112953A1 (en) *	2006-10-06	2008-05-15	Amgen Inc.	Stable formulations
AU2012200284B2 (en) *	2006-10-06	2014-03-06	Amgen Inc.	Stable Antibody Formulations
KR100784134B1 (ko)	2006-10-09	2007-12-12	주식회사 대웅	상피세포성장인자를 함유하는 안정한 구내염 치료용 액상조성물
WO2008051363A2 (fr)	2006-10-20	2008-05-02	Amgen Inc.	Formulations stables de polypeptide
JP5732196B2 (ja) *	2006-11-01	2015-06-10	バイオジェンアイデックエムエーインコーポレイティドＢｉｏｇｅｎＩｄｅｃＩｎｃ．	低ｐＨおよび二価カチオンを用いる生物高分子を単離する方法
US20100189721A1 (en) *	2007-07-06	2010-07-29	Smithkline Beecham Corporation	Antibody formulations
UA107557C2 (xx) *	2007-07-06	2015-01-26		Композиція антитіла офатумумабу
CN101687038A (zh) *	2007-07-10	2010-03-31	霍夫曼-拉罗奇有限公司	新型制剂
EP2205276A4 (fr) *	2007-09-28	2012-08-15	Janssen Biotech Inc	Anticorps anti-il-12/23p40, épitopes, formulations, compositions, procédés et utilisations
SG10201405835TA (en)	2007-11-12	2014-10-30	U3 Pharma Gmbh	Axl antibodies
PE20091174A1 (es) *	2007-12-27	2009-08-03	Chugai Pharmaceutical Co Ltd	Formulacion liquida con contenido de alta concentracion de anticuerpo
MX2010014079A (es) *	2008-06-20	2011-02-22	Novartis Ag	Inmunoglobulinas con agregacion reducida.
TWI445716B (zh) *	2008-09-12	2014-07-21	Rinat Neuroscience Corp	Ｐｃｓｋ９拮抗劑類
TR201802935T4 (tr) *	2008-09-19	2018-03-21	Pfizer	Stabil sıvı antikor formülasyonu.
PE20110302A1 (es) *	2008-09-19	2011-05-21	Hoffmann La Roche	Formulacion farmaceutica de un anticuerpo contra p-selectina
CA2738243C (fr)	2008-10-29	2020-09-29	Wyeth Llc	Formulations de molecules de liaison d'antigene monodomaines
CN102272154A (zh)	2008-10-29	2011-12-07	惠氏有限责任公司	单域抗原结合性分子的纯化方法
JP2012510468A (ja) *	2008-11-28	2012-05-10	アボット・ラボラトリーズ	安定な抗体組成物およびこれを安定させるための方法
EP2196476A1 (fr) *	2008-12-10	2010-06-16	Novartis Ag	Formulation d'anticorps
TWI526223B (zh)	2009-05-11	2016-03-21	Ｕ３製藥有限責任公司	人化ａｘｌ抗體類
CA2765220A1 (fr) *	2009-07-14	2011-01-20	Biogen Idec Ma Inc.	Procedes pour l'inhibition de la formation de couleur jaune et du peroxyde dans une composition
ES2604103T3 (es) *	2009-10-01	2017-03-03	F. Hoffmann-La Roche Ag	Filtración final de una preparación de inmunoglobulina en múltiples pasos
EA201892184A1 (ru)	2010-03-01	2019-03-29	БАЙЕР ХЕЛЬСКЕР ЛЛСи	Оптимизированные моноклональные антитела против ингибитора пути тканевого фактора
AR080698A1 (es)	2010-04-01	2012-05-02	Imclone Llc	Anticuerpo o fragmento del mismo que especificamente enlaza la variante de csf -1r humano, composicion farmaceutica que lo comprende, su uso para la manufactura de un medicamento util para el tratamiento de cancer y metodo para determinar si un sujeto es candidato para tratamiento de cancer basado e
EP3326645B1 (fr)	2010-10-25	2020-03-18	Biogen MA Inc.	Procédés de détermination de différences dans l'activité alpha-4 intégrine par la corrélation de différences des taux de svcam et/ou de smadcam
HUE044038T2 (hu) *	2010-11-05	2019-09-30	Novartis Ag	Spondilitisz ankilopoetika kezelési eljárásai anti-IL-17 alkalmazásával
JP5458188B2 (ja) *	2011-02-17	2014-04-02	協和発酵キリン株式会社	抗ｃｄ４０抗体の高濃度製剤
LT2704742T (lt)	2011-05-02	2017-10-25	Millennium Pharmaceuticals, Inc.	Anti-alfa4beta7 antikūno kompozicija
AU2012285875B2 (en) *	2011-07-18	2016-11-10	Morphosys Ag	Use of c-Fms antagonists
US20130064811A1 (en) *	2011-09-09	2013-03-14	International Business Machines Corporation	Methods to Enhance Cancer Treatment
EP2809350B1 (fr) *	2012-01-30	2018-10-17	Arecor Limited	Compositions aqueuses d'anticorps stabilisées
US20150150979A1 (en) *	2012-06-21	2015-06-04	Ucb Pharma, S.A.	Pharmaceutical formulation
US9592297B2 (en)	2012-08-31	2017-03-14	Bayer Healthcare Llc	Antibody and protein formulations
MX2015009901A (es)	2013-02-01	2016-04-06	Santa Maria Biotherapeutics Inc	Administración de un compuesto de antiactivina a a un sujeto.
WO2014159659A1 (fr) *	2013-03-12	2014-10-02	Stein Emily A	Composition dentaire comprenant un chélateur et une base
AU2014229282B2 (en)	2013-03-15	2017-02-02	Glaxosmithkline Intellectual Property (No.2) Limited	Low concentration antibody formulations
CN105121466A (zh)	2013-04-12	2015-12-02	莫佛塞斯公司	靶向m-csf的抗体
CN106170298B (zh)	2013-10-16	2024-01-09	前瞻疗法公司	用于提高抗体稳定性的缓冲液制剂
JP2014062100A (ja) *	2013-11-05	2014-04-10	Glaxosmithkline Llc	抗体処方
EP2946766B1 (fr)	2014-05-23	2016-03-02	Ares Trading S.A.	Composition pharmaceutique liquide
EP3050557A1 (fr)	2014-05-23	2016-08-03	Ares Trading S.A.	Composition pharmaceutique liquide
CN105296433B (zh) *	2014-08-01	2018-02-09	中山康方生物医药有限公司	一种ctla4抗体、其药物组合物及其用途
CA3093383A1 (fr)	2014-10-24	2016-04-28	Merck Sharp & Dohme Corp.	Co-agonistes des recepteurs du glucagon et du glp-1
CN104357394B (zh) *	2014-10-24	2017-03-22	杭州阿诺生物医药科技股份有限公司	一种自体外周血淋巴细胞dc‑cik的培养方法
CN105669867A (zh) *	2014-11-21	2016-06-15	上海中信国健药业股份有限公司	抗gitr/ctla-4双特异性抗体及其制备方法和用途
AR103173A1 (es)	2014-12-22	2017-04-19	Novarits Ag	Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
CA2916283C (fr)	2015-01-09	2024-07-02	Pfizer Inc.	Regime de dosage pour antagonistes de madcam
US10696735B2 (en)	2015-01-21	2020-06-30	Outlook Therapeutics, Inc.	Modulation of charge variants in a monoclonal antibody composition
CN118638229A (zh)	2015-01-30	2024-09-13	动量制药公司	Fcrn抗体及其使用方法
EP3053572A1 (fr) *	2015-02-06	2016-08-10	Ares Trading S.A.	Composition pharmaceutique liquide
JP6247241B2 (ja) *	2015-02-27	2017-12-13	ノバルティスアーゲー	抗体処方
KR20250004095A (ko)	2015-04-17	2025-01-07	브리스톨-마이어스 스큅 컴퍼니	항-pd-1 항체 및 또 다른 항체의 조합물을 포함하는 조성물
WO2016183469A1 (fr) *	2015-05-13	2016-11-17	Robert Kirken	Blocage anti-ctla -4
SI3303394T1 (sl)	2015-05-29	2020-10-30	Agenus Inc.	Protitelesa proti-CTLA-4 in postopki njihove uporabe
AR104847A1 (es) *	2015-06-17	2017-08-16	Lilly Co Eli	Formulación de anticuerpo anti-cgrp
WO2017051273A1 (fr) *	2015-09-22	2017-03-30	Pfizer Inc.	Procédé de préparation d'une formulation de protéine thérapeutique et formulation d'anticorps produite par un tel procédé
CN106620691B (zh) *	2015-11-04	2020-08-21	信达生物制药(苏州)有限公司	一种重组全人源抗ctla-4单克隆抗体制剂及其应用
CA3010987A1 (fr)	2016-01-08	2017-07-13	Replimune Limited	Lignee de virus de l'herpes simplex oncolytique de type i
EP3400023A1 (fr) *	2016-01-10	2018-11-14	ModernaTX, Inc.	Arnm thérapeutiques codant pour des anticorps anti-ctla-4
MX2018009341A (es)	2016-02-03	2019-05-15	Oncobiologics Inc	Formulaciones tamponadas para una mayor estabilidad de anticuerpos.
GB201604124D0 (en) *	2016-03-10	2016-04-27	Ucb Biopharma Sprl	Pharmaceutical formulation
CN105777858B (zh) *	2016-03-22	2019-09-10	东软威特曼生物科技(南京)有限公司	多种抗体的复合稳定剂及其使用方法
US11542332B2 (en)	2016-03-26	2023-01-03	Bioatla, Inc.	Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof
EP3448428A4 (fr) *	2016-04-25	2019-11-27	Medimmune, LLC	Compositions comprenant une co-formulation d'anticorps anti-pd-l1 et anti-ctla-4
JP7461741B2 (ja)	2016-06-20	2024-04-04	カイマブ・リミテッド	抗ｐｄ－ｌ１およびｉｌ－２サイトカイン
WO2018035710A1 (fr)	2016-08-23	2018-03-01	Akeso Biopharma, Inc.	Anticorps anti-ctla4
CN107815467B (zh)	2016-08-31	2021-03-16	百奥赛图(北京)医药科技股份有限公司	人源化基因改造动物模型的制备方法及应用
CN107815468B (zh)	2016-08-31	2021-03-16	百奥赛图(北京)医药科技股份有限公司	人源化基因改造动物模型的制备方法及应用
WO2018041121A1 (fr)	2016-08-31	2018-03-08	Beijing Biocytogen Co., Ltd	Animal non humain génétiquement modifié avec un ctla-4 humain ou chimérique
WO2018098352A2 (fr)	2016-11-22	2018-05-31	Jun Oishi	Ciblage d'expression du point de contrôle immunitaire induit par kras
CN106432499A (zh) *	2016-11-24	2017-02-22	上海美迪西生物医药股份有限公司	Ctla‑4抗体fab在昆虫表达系统中的制备方法
IL266918B2 (en)	2016-12-07	2024-03-01	Agenus Inc	Anti-ctla-4 antibodies and methods of use thereof
GB201700350D0 (en)	2017-01-09	2017-02-22	Replimune Ltd	Altered virus
US11608357B2 (en)	2018-08-28	2023-03-21	Arecor Limited	Stabilized antibody protein solutions
GB201703062D0 (en)	2017-02-24	2017-04-12	Arecor Ltd	Stabilized antibody protein solutions
EP3372242A1 (fr)	2017-03-06	2018-09-12	Ares Trading S.A.	Composition pharmaceutique liquide
EP3372241A1 (fr)	2017-03-06	2018-09-12	Ares Trading S.A.	Composition pharmaceutique liquide
CN106913869B (zh) *	2017-03-17	2020-07-28	信达生物制药(苏州)有限公司	一种抗ctla-4单克隆抗体制剂及其应用
WO2018204374A1 (fr)	2017-05-02	2018-11-08	Merck Sharp & Dohme Corp.	Formulations d'anticorps anti-lag3 etco-formulations d'anticorps anti-lag3 et d'anticorps anti-pd-1
UA129862C2 (uk) *	2017-05-02	2025-08-27	Мерк Шарп Енд Доум Елелсі	Склад для лікування злоякісної пухлини або хронічної інфекції
JOP20190260A1 (ar)	2017-05-02	2019-10-31	Merck Sharp & Dohme	صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
CN111010866A (zh)	2017-05-24	2020-04-14	潘迪恩治疗公司	靶向免疫耐受性
WO2019006003A1 (fr) *	2017-06-27	2019-01-03	The Trustees Of Princeton University	Compositions et procédés pour améliorer une immunothérapie
CR20200076A (es)	2017-07-14	2020-06-10	Pfizer	ANTICUERPOS CONTRA MAdCAM
HRP20240485T1 (hr)	2017-08-24	2024-07-05	Novo Nordisk A/S	Pripravci glp-1 i njihova upotreba
KR102816741B1 (ko)	2017-08-31	2025-06-04	다이이찌 산쿄 가부시키가이샤	항체-약물 콘주게이트의 개량 제조 방법
ES2991988T3 (es)	2017-10-30	2024-12-05	Takeda Pharmaceuticals Co	Detergentes compatibles con el medio ambiente para la inactivación de virus con envoltura lipídica
US10946068B2 (en)	2017-12-06	2021-03-16	Pandion Operations, Inc.	IL-2 muteins and uses thereof
US10174092B1 (en)	2017-12-06	2019-01-08	Pandion Therapeutics, Inc.	IL-2 muteins
JP7420720B2 (ja)	2017-12-13	2024-01-23	モメンタファーマシューティカルズインコーポレイテッド	ＦｃＲｎ抗体およびその使用方法
US11324774B2 (en)	2018-01-05	2022-05-10	Augusta University Research Institute, Inc.	Compositions of oral alkaline salts and metabolic acid inducers and uses thereof
IL277095B2 (en) *	2018-03-07	2025-10-01	Pfizer	Preparations containing anti-PD-1 antibody
MX2021000790A (es) *	2018-07-20	2021-07-21	Momenta Pharmaceuticals Inc	Composiciones de anticuerpos del receptor neonatal para fc y metodos de uso de las mismas.
JP2021533163A (ja) *	2018-08-07	2021-12-02	ザブリガムアンドウィメンズホスピタルインコーポレイテッドThe Brigham and Women’s Hospital, Inc.	アネキシンａ１を介した心血管石灰化の阻害に関する方法および組成物
US11819504B2 (en)	2018-08-26	2023-11-21	Attain Health Inc.	Methods and compositions to increase hair growth and/or prevent hair loss
IL291545B1 (en) *	2018-10-31	2025-09-01	Bioatla Llc	Anti-CTLA4 antibodies, antibody fragments, immunoconjugates thereof and uses thereof
KR20210089215A (ko)	2018-11-07	2021-07-15	머크 샤프 앤드 돔 코포레이션	항-lag3 항체 및 항-pd-1 항체의 공동-제제
US11739146B2 (en)	2019-05-20	2023-08-29	Pandion Operations, Inc.	MAdCAM targeted immunotolerance
BR112021024112A2 (pt)	2019-06-04	2022-03-22	Jiangsu Hengrui Medicine Co	Anticorpo capaz de se ligar à linfopoietina estromal tímica e uso do mesmo
BR112022004941A2 (pt)	2019-09-20	2022-06-28	Novartis Ag	Métodos para tratar doenças autoimunes com o uso de antagonistas de interleucina-17 (il-17)
KR20220069043A (ko) *	2019-09-23	2022-05-26	머크 샤프 앤드 돔 코포레이션	감소된 숙주 세포 단백질 및 증가된 폴리소르베이트-80 안정성을 갖는 항-ctla4 모노클로날 항체를 포함하는 방법 및 조성물
BR112022007635A2 (pt) *	2019-11-13	2022-07-12	Pfizer	Formulação aquosa e estável de anticorpos
CN114793422A (zh) *	2019-12-25	2022-07-26	百奥泰生物制药股份有限公司	抗ctla-4单克隆抗体及其制备方法与应用
MX2022009844A (es)	2020-02-18	2022-09-05	Novo Nordisk As	Composiciones y usos del peptido similar al glucagon-1 (glp-1).
US11981715B2 (en)	2020-02-21	2024-05-14	Pandion Operations, Inc.	Tissue targeted immunotolerance with a CD39 effector
EP4153130A1 (fr) *	2020-05-19	2023-03-29	F. Hoffmann-La Roche AG	Utilisation de chélateurs pour la prévention de la formation de particules visibles dans des solutions de protéines parentérales
WO2022026914A1 (fr) *	2020-07-31	2022-02-03	Alamab Therapeutics, Inc.	Formulations d'anticorps anti-connexine
AR123340A1 (es) *	2020-08-26	2022-11-23	Janssen Biotech Inc	FORMULACIONES ESTABLES QUE COMPRENDEN UN ANTICUERPO BIESPECÍFICO PARA EGFR / c-MET
CA3194602A1 (fr) *	2020-10-06	2022-04-14	Abraham Oommen	Methode de detection d'arn ou d'adn a partir d'echantillons biologiques
WO2022106976A1 (fr)	2020-11-18	2022-05-27	Pfizer Inc.	Formulations pharmaceutiques stables de leurres de fgfr3 solubles
TWI891945B (zh) *	2020-12-03	2025-08-01	大陸商江蘇恒瑞醫藥股份有限公司	抗tslp抗體藥物組合物及其用途
CN112569183B (zh) *	2020-12-11	2022-12-09	上海赛金生物医药有限公司	一种抗ctla-4抗体及融合蛋白的制剂
TW202308689A (zh) *	2021-04-21	2023-03-01	美商健生生物科技公司	高濃度的雙特異性抗體調配物
JP2025536574A (ja) *	2022-11-04	2025-11-07	アストラゼネカ・アクチエボラーグ	抗ｃｔｌａ抗体組成物及び関連方法
JP2025538586A (ja)	2022-11-22	2025-11-28	武田薬品工業株式会社	非アルコール性脂肪性肝炎の治療のためのＭＡｄＣＡＭ－１抗体の投薬レジメン
WO2024186990A1 (fr) *	2023-03-09	2024-09-12	Merck Sharp & Dohme Llc	Formulations comprenant des variants de protéine actriia
WO2025149667A1 (fr)	2024-01-12	2025-07-17	Pheon Therapeutics Ltd	Conjugués anticorps-médicament et leurs utilisations

Family Cites Families (91)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4634665A (en)	1980-02-25	1987-01-06	The Trustees Of Columbia University In The City Of New York	Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en)	1980-02-25	1993-01-12	The Trustees Of Columbia University In The City Of New York	Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en)	1980-02-25	1983-08-16	The Trustees Of Columbia University	Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4510245A (en)	1982-11-18	1985-04-09	Chiron Corporation	Adenovirus promoter system
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
US4740461A (en)	1983-12-27	1988-04-26	Genetics Institute, Inc.	Vectors and methods for transformation of eucaryotic cells
US4597966A (en) *	1985-01-09	1986-07-01	Ortho Diagnostic Systems, Inc.	Histidine stabilized immunoglobulin and method of preparation
US5168062A (en)	1985-01-30	1992-12-01	University Of Iowa Research Foundation	Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
CA1319120C (fr)	1985-04-01	1993-06-15	John Henry Kenten	Lignee cellulaire myelomateuse transformee et expression d'un gene codant pour un polypeptide d'eucaryote a l'aide de cette lignee
US4968615A (en)	1985-12-18	1990-11-06	Ciba-Geigy Corporation	Deoxyribonucleic acid segment from a virus
GB8601597D0 (en)	1986-01-23	1986-02-26	Wilson R H	Nucleotide sequences
US4959455A (en)	1986-07-14	1990-09-25	Genetics Institute, Inc.	Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
US4912040A (en)	1986-11-14	1990-03-27	Genetics Institute, Inc.	Eucaryotic expression system
RU1438240C (ru)	1987-04-22	1996-03-20	Институт биоорганической химии им.М.М.Шемякина и Ю.А.Овчинникова РАН	РЕКОМБИНАНТНАЯ ПЛАЗМИДНАЯ ДНК РТNF 22, СОДЕРЖАЩАЯ ПОЛУСИНТЕТИЧЕСКИЙ ГЕН ФАКТОРА НЕКРОЗА ОПУХОЛИ ЧЕЛОВЕКА - ПРОМЕЖУТОЧНАЯ ПЛАЗМИДА ДЛЯ КОНСТРУИРОВАНИЯ РЕКОМБИНАНТНОЙ ПЛАЗМИДНОЙ ДНК pTNF 31, КОДИРУЮЩАЯ ПОЛИПЕПТИД СО СВОЙСТВАМИ ФАКТОРА НЕКРОЗА ОПУХОЛИ ЧЕЛОВЕКА, И ШТАММ БАКТЕРИЙ ESCHERICHIA COLI - ПРОДУЦЕНТ ПОЛИПЕПТИДА СО СВОЙСТВАМИ ФАКТОРА НЕКРОЗА ОПУХОЛИ ЧЕЛОВЕКА
US5750172A (en)	1987-06-23	1998-05-12	Pharming B.V.	Transgenic non human mammal milk
GB8717430D0 (en)	1987-07-23	1987-08-26	Celltech Ltd	Recombinant dna product
GB8823869D0 (en)	1988-10-12	1988-11-16	Medical Res Council	Production of antibodies
US5175384A (en)	1988-12-05	1992-12-29	Genpharm International	Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5633076A (en)	1989-12-01	1997-05-27	Pharming Bv	Method of producing a transgenic bovine or transgenic bovine embryo
US6673986B1 (en)	1990-01-12	2004-01-06	Abgenix, Inc.	Generation of xenogeneic antibodies
ATE139258T1 (de)	1990-01-12	1996-06-15	Cell Genesys Inc	Erzeugung xenogener antikörper
US6075181A (en)	1990-01-12	2000-06-13	Abgenix, Inc.	Human antibodies derived from immunized xenomice
US6150584A (en)	1990-01-12	2000-11-21	Abgenix, Inc.	Human antibodies derived from immunized xenomice
US5217954A (en) *	1990-04-04	1993-06-08	Scios Nova Inc.	Formulations for stabilizing fibroblast growth factor
US5151510A (en)	1990-04-20	1992-09-29	Applied Biosystems, Inc.	Method of synethesizing sulfurized oligonucleotide analogs
US5789650A (en)	1990-08-29	1998-08-04	Genpharm International, Inc.	Transgenic non-human animals for producing heterologous antibodies
US5625126A (en)	1990-08-29	1997-04-29	Genpharm International, Inc.	Transgenic non-human animals for producing heterologous antibodies
US5633425A (en)	1990-08-29	1997-05-27	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
US5770429A (en)	1990-08-29	1998-06-23	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en)	1990-08-29	1996-08-13	Genpharm International, Inc.	Ransgenic non-human animals for producing heterologous antibodies
AU664976B2 (en)	1990-08-29	1995-12-14	Gene Pharming Europe Bv	Homologous recombination in mammalian cells
US5661016A (en)	1990-08-29	1997-08-26	Genpharm International Inc.	Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
AU8507191A (en)	1990-08-29	1992-03-30	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
US5814318A (en)	1990-08-29	1998-09-29	Genpharm International Inc.	Transgenic non-human animals for producing heterologous antibodies
US5851795A (en)	1991-06-27	1998-12-22	Bristol-Myers Squibb Company	Soluble CTLA4 molecules and uses thereof
AU2515992A (en)	1991-08-20	1993-03-16	Genpharm International, Inc.	Gene targeting in animal cells using isogenic dna constructs
JPH0595794A (ja) *	1991-10-04	1993-04-20	Otsuka Pharmaceut Co Ltd	ヒトｍ−ｃｓｆ抗体及びヒトｍ−ｃｓｆの測定法
GB9122820D0 (en) *	1991-10-28	1991-12-11	Wellcome Found	Stabilised antibodies
JP2942412B2 (ja) *	1991-12-26	1999-08-30	鐘紡株式会社	化粧料
NZ255101A (en)	1992-07-24	1997-08-22	Cell Genesys Inc	A yeast artificial chromosome (yac) vector containing an hprt minigene expressible in murine stem cells and genetically modified rodent therefor
US5589167A (en) *	1993-02-23	1996-12-31	Genentech, Inc.	Excipient stabilization of polypeptides treated with organic solvents
DK0804070T3 (da)	1993-03-09	2000-08-07	Genzyme Corp	Fremgangsmåde til isolering af proteiner fra mælk
US5827690A (en)	1993-12-20	1998-10-27	Genzyme Transgenics Corporatiion	Transgenic production of antibodies in milk
US5643763A (en)	1994-11-04	1997-07-01	Genpharm International, Inc.	Method for making recombinant yeast artificial chromosomes by minimizing diploid doubling during mating
US7803904B2 (en) *	1995-09-01	2010-09-28	Millennium Pharmaceuticals, Inc.	Mucosal vascular addressing and uses thereof
US6091001A (en)	1995-03-29	2000-07-18	Abgenix, Inc.	Production of antibodies using Cre-mediated site-specific recombination
US6130364A (en)	1995-03-29	2000-10-10	Abgenix, Inc.	Production of antibodies using Cre-mediated site-specific recombination
AU705616B2 (en)	1995-04-21	1999-05-27	Cell Genesys, Inc.	Generation of large genomic DNA deletions
EP0822830B1 (fr)	1995-04-27	2008-04-02	Amgen Fremont Inc.	Anticorps anti-IL-8 dérivés de xenosouris immunisées
EP0823941A4 (fr)	1995-04-28	2001-09-19	Abgenix Inc	Anticorps humains derives de xeno-souris immunisees
US6267958B1 (en) *	1995-07-27	2001-07-31	Genentech, Inc.	Protein formulation
US20020081294A1 (en) *	1996-01-23	2002-06-27	Genentech, Inc.	Co-administration of a thrombolytic and an anti-CD18 antibody in stroke
US5714352A (en)	1996-03-20	1998-02-03	Xenotech Incorporated	Directed switch-mediated DNA recombination
US5994619A (en)	1996-04-01	1999-11-30	University Of Massachusetts, A Public Institution Of Higher Education Of The Commonwealth Of Massachusetts, As Represented By Its Amherst Campus	Production of chimeric bovine or porcine animals using cultured inner cell mass cells
GB9610992D0 (en)	1996-05-24	1996-07-31	Glaxo Group Ltd	Concentrated antibody preparation
US5916771A (en)	1996-10-11	1999-06-29	Abgenix, Inc.	Production of a multimeric protein by cell fusion method
EP1500329B1 (fr)	1996-12-03	2012-03-21	Amgen Fremont Inc.	Les anticorps humains qui lient en particulier l'alpha de TNF humain
US6235883B1 (en)	1997-05-05	2001-05-22	Abgenix, Inc.	Human monoclonal antibodies to epidermal growth factor receptor
JP3919235B2 (ja) *	1997-06-13	2007-05-23	ジェネンテク，インコーポレイテッド	抗体製剤
US6171586B1 (en) *	1997-06-13	2001-01-09	Genentech, Inc.	Antibody formulation
WO1999045031A2 (fr)	1998-03-03	1999-09-10	Abgenix, Inc.	Molecules fixatrices cd147 utilisees comme agents therapeutiques
US20020029391A1 (en)	1998-04-15	2002-03-07	Claude Geoffrey Davis	Epitope-driven human antibody production and gene expression profiling
US20020142374A1 (en)	1998-08-17	2002-10-03	Michael Gallo	Generation of modified molecules with increased serum half-lives
EE05627B1 (et) *	1998-12-23	2013-02-15	Pfizer Inc.	CTLA-4 vastased inimese monoklonaalsed antikehad
SI2112166T1 (sl) *	1998-12-23	2019-05-31	Pfizer Inc.	Človeška monoklonska protitelesa proti CTLA-4
US7605238B2 (en)	1999-08-24	2009-10-20	Medarex, Inc.	Human CTLA-4 antibodies and their uses
CN1371416B (zh) *	1999-08-24	2012-10-10	梅达里克斯公司	人ctla-4抗体及其应用
US6517529B1 (en)	1999-11-24	2003-02-11	Radius International Limited Partnership	Hemodialysis catheter
EP1336410A4 (fr) *	2000-08-04	2005-10-12	Chugai Pharmaceutical Co Ltd	Preparations proteiniques a injecter
DK1314437T3 (da) *	2000-08-11	2014-07-14	Chugai Pharmaceutical Co Ltd	Stabiliserede antistofindeholdende præparater
IL149701A0 (en)	2001-05-23	2002-11-10	Pfizer Prod Inc	Use of anti-ctla-4 antibodies
CA2454587C (fr) *	2001-07-25	2012-11-13	Protein Design Labs, Inc.	Formulation pharmaceutique lyophilisee stable d'anticorps igg
IL161677A0 (en) *	2001-11-08	2004-09-27	Protein Design Labs	Stable liquid pharmaceutical formulation of igg antibodies
US7330415B2 (en) *	2001-11-15	2008-02-12	Koninklijke Philips Electronics N. V.	Optical record carrier recording method and recording apparatus
US7452539B2 (en) *	2001-12-19	2008-11-18	Genentech, Inc.	Stabilizing polypeptides which have been exposed to urea
MXPA04007924A (es)	2002-02-14	2005-05-17	Chugai Pharmaceutical Co Ltd	Formulaciones en solucion que contienen anticuerpo.
US7132100B2 (en) *	2002-06-14	2006-11-07	Medimmune, Inc.	Stabilized liquid anti-RSV antibody formulations
WO2004001007A2 (fr) *	2002-06-21	2003-12-31	Idec Pharmaceuticals Corporation	Preparations tamponnees permettant de concentrer des anticorps et procedes pour les utiliser
WO2004007520A2 (fr) *	2002-07-12	2004-01-22	Medarex, Inc.	Procedes et compositions visant a prevenir la degradation oxydative de proteines
CA2505994A1 (fr) *	2002-11-15	2004-06-03	Chiron Corporation	Procedes de prevention et de traitement de metastase cancereuse et de perte osseuse liee a la metastase cancereuse
US20040191243A1 (en) *	2002-12-13	2004-09-30	Bei Chen	System and method for stabilizing antibodies with histidine
RU2358763C2 (ru) *	2003-02-10	2009-06-20	Элан Фармасьютикалз, Инк.	Композиции иммуноглобулина и способ их получения
DK2335725T3 (en) *	2003-04-04	2017-01-23	Genentech Inc	Highly concentrated antibody and protein formulations
AR045563A1 (es)	2003-09-10	2005-11-02	Warner Lambert Co	Anticuerpos dirigidos a m-csf
EP1709080B1 (fr) *	2004-01-09	2011-03-09	Pfizer Inc.	ANTICORPS A MAdCAM
US20060008415A1 (en) *	2004-06-25	2006-01-12	Protein Design Labs, Inc.	Stable liquid and lyophilized formulation of proteins
JO3000B1 (ar) *	2004-10-20	2016-09-05	Genentech Inc	مركبات أجسام مضادة .
AU2006208226A1 (en) *	2005-01-24	2006-08-03	Amgen Inc.	Humanized anti-amyloid antibody
JP2006249082A (ja) *	2005-03-08	2006-09-21	Pharmacia & Upjohn Co Llc	低減レベルの内毒素を有する抗ｍ−ｃｓｆ抗体組成物
KR100996801B1 (ko) *	2005-03-08	2010-11-25	파마시아 앤드 업존 캄파니 엘엘씨	항-ＭＡｄＣＡＭ 항체 조성물
CA2613017A1 (fr) *	2005-07-08	2007-01-18	Pfizer Limited	Utilisation d'anticorps anti-madcam pour le traitement de la maladie coeliaque et de la sprue tropicale

2006
- 2006-03-02 KR KR1020077020428A patent/KR100996801B1/ko not_active Expired - Fee Related
- 2006-03-02 AR ARP060100793A patent/AR053026A1/es not_active Application Discontinuation
- 2006-03-02 SI SI200632306T patent/SI2620450T1/sl unknown
- 2006-03-02 AU AU2006220828A patent/AU2006220828A1/en not_active Abandoned
- 2006-03-02 JP JP2006056818A patent/JP2006249084A/ja active Pending
- 2006-03-02 US US11/817,898 patent/US20080248047A1/en not_active Abandoned
- 2006-03-02 US US11/817,894 patent/US9487581B2/en active Active
- 2006-03-02 MX MX2007010971A patent/MX2007010971A/es active IP Right Grant
- 2006-03-02 LT LTEP13155091.5T patent/LT2620450T/lt unknown
- 2006-03-02 CA CA2600434A patent/CA2600434C/fr active Active
- 2006-03-02 PL PL13155091T patent/PL2620450T3/pl unknown
- 2006-03-02 JP JP2006056870A patent/JP2006249085A/ja active Pending
- 2006-03-02 AR ARP060100794A patent/AR053553A1/es not_active Application Discontinuation
- 2006-03-02 SI SI200632037A patent/SI1865986T1/sl unknown
- 2006-03-02 WO PCT/US2006/007554 patent/WO2006096490A2/fr not_active Ceased
- 2006-03-02 WO PCT/US2006/007461 patent/WO2006096461A2/fr not_active Ceased
- 2006-03-02 US US11/817,993 patent/US20090110681A1/en not_active Abandoned
- 2006-03-02 WO PCT/US2006/007551 patent/WO2006096488A2/fr not_active Ceased
- 2006-03-02 DK DK13155091.5T patent/DK2620450T3/en active
- 2006-03-02 US US11/815,259 patent/US20090238820A1/en not_active Abandoned
- 2006-03-02 WO PCT/US2006/007555 patent/WO2006096491A2/fr not_active Ceased
- 2006-03-02 EP EP10185318A patent/EP2311491A1/fr not_active Withdrawn
- 2006-03-02 EP EP06736812.6A patent/EP1865986B1/fr active Active
- 2006-03-02 HU HUE06736812A patent/HUE028410T2/en unknown
- 2006-03-02 EP EP06736810A patent/EP1858552A2/fr not_active Withdrawn
- 2006-03-02 JP JP2006056701A patent/JP5670004B2/ja active Active
- 2006-03-02 AR AR20060100796A patent/AR054233A1/es not_active Application Discontinuation
- 2006-03-02 TW TW095107087A patent/TW200642694A/zh unknown
- 2006-03-02 ES ES13155091T patent/ES2707284T3/es active Active
- 2006-03-02 TW TW095107021A patent/TWI365747B/zh active
- 2006-03-02 DK DK06736812.6T patent/DK1865986T3/en active
- 2006-03-02 CA CA002600588A patent/CA2600588A1/fr not_active Abandoned
- 2006-03-02 BR BRPI0608815-5A patent/BRPI0608815B1/pt active IP Right Grant
- 2006-03-02 TW TW095107035A patent/TW200719913A/zh unknown
- 2006-03-02 JP JP2006056813A patent/JP2006249083A/ja active Pending
- 2006-03-02 EP EP06736811A patent/EP1871806A2/fr not_active Withdrawn
- 2006-03-02 EP EP06748276A patent/EP1868646A2/fr not_active Withdrawn
- 2006-03-02 AR ARP060100795A patent/AR062247A1/es not_active Application Discontinuation
- 2006-03-02 NZ NZ560844A patent/NZ560844A/en unknown
- 2006-03-02 ES ES06736812.6T patent/ES2569409T3/es active Active
- 2006-03-02 BR BRPI0608855-4A patent/BRPI0608855A2/pt not_active IP Right Cessation
- 2006-03-02 HU HUE13155091A patent/HUE041802T2/hu unknown
- 2006-03-02 MX MX2007010970A patent/MX2007010970A/es unknown
- 2006-03-02 NZ NZ561137A patent/NZ561137A/en unknown
- 2006-03-02 AU AU2006220829A patent/AU2006220829C1/en active Active
- 2006-03-02 CA CA002600608A patent/CA2600608A1/fr not_active Abandoned
- 2006-03-02 PT PT13155091T patent/PT2620450T/pt unknown
- 2006-03-02 KR KR1020077020433A patent/KR100989280B1/ko active Active
- 2006-03-02 CN CN201410109866.6A patent/CN103861102A/zh active Pending
- 2006-03-02 EP EP13155091.5A patent/EP2620450B1/fr active Active
- 2006-03-02 CA CA002600836A patent/CA2600836A1/fr not_active Abandoned
- 2006-03-03 TW TW095107092A patent/TW200709817A/zh unknown
2007
- 2007-08-20 IL IL185380A patent/IL185380A0/en unknown
- 2007-08-23 IL IL185483A patent/IL185483A/en active IP Right Grant
2010
- 2010-09-10 US US12/879,916 patent/US20110027262A1/en not_active Abandoned
2012
- 2012-05-21 JP JP2012115478A patent/JP2012167120A/ja active Pending
- 2012-10-31 JP JP2012240979A patent/JP2013032387A/ja not_active Withdrawn
2013
- 2013-03-21 IL IL225435A patent/IL225435A0/en unknown
2015
- 2015-03-04 JP JP2015042425A patent/JP6212509B2/ja active Active
2019
- 2019-01-11 CY CY20191100026T patent/CY1121254T1/el unknown
2023
- 2023-07-28 FR FR23C1029C patent/FR23C1029I2/fr active Active
- 2023-07-28 NL NL301240C patent/NL301240I2/nl unknown
- 2023-08-01 LU LU00312C patent/LUC00312I2/en unknown
- 2023-08-02 FI FIC20230027C patent/FIC20230027I1/fi unknown
- 2023-08-09 CY CY2023018C patent/CY2023018I2/el unknown
- 2023-08-09 LT LTPA2023522C patent/LTC2620450I2/lt unknown
- 2023-08-17 HU HUS2300026C patent/HUS2300026I1/hu unknown

Also Published As

Publication number	Publication date
WO2006096488A3 (fr)	2006-11-30
SI1865986T1 (sl)	2016-05-31
US20110027262A1 (en)	2011-02-03
AR053026A1 (es)	2007-04-18
CA2600434A1 (fr)	2006-09-14
WO2006096461A2 (fr)	2006-09-14
IL185380A0 (en)	2008-02-09
DK2620450T3 (en)	2019-02-04
JP2012167120A (ja)	2012-09-06
WO2006096490A8 (fr)	2007-02-01
FR23C1029I2 (fr)	2024-06-14
MX2007010971A (es)	2007-09-19
TW200709817A (en)	2007-03-16
CA2600434C (fr)	2017-09-19
AU2006220829B2 (en)	2011-10-13
TW200700081A (en)	2007-01-01
JP2006249081A (ja)	2006-09-21
JP2006249083A (ja)	2006-09-21
CY2023018I2 (el)	2024-02-16
EP1871806A2 (fr)	2008-01-02
US9487581B2 (en)	2016-11-08
EP1868646A2 (fr)	2007-12-26
EP2311491A1 (fr)	2011-04-20
KR100989280B1 (ko)	2010-10-20
WO2006096490A2 (fr)	2006-09-14
WO2006096491A2 (fr)	2006-09-14
EP2620450A3 (fr)	2014-01-08
MX2007010970A (es)	2007-09-19
HUE041802T2 (hu)	2019-05-28
FIC20230027I1 (fi)	2023-08-02
JP5670004B2 (ja)	2015-02-18
WO2006096491A3 (fr)	2007-03-29
EP2620450A2 (fr)	2013-07-31
IL185483A0 (en)	2008-01-06
CA2600588A1 (fr)	2006-09-14
EP1865986B1 (fr)	2016-02-17
CA2600608A1 (fr)	2006-09-14
WO2006096488A2 (fr)	2006-09-14
PL2620450T3 (pl)	2019-05-31
LTC2620450I2 (fr)	2024-11-11
AU2006220829C1 (en)	2025-01-02
BRPI0608815B1 (pt)	2021-10-13
US20090110681A1 (en)	2009-04-30
CN103861102A (zh)	2014-06-18
SI2620450T1 (sl)	2019-01-31
JP2015110656A (ja)	2015-06-18
LTPA2023522I1 (fr)	2023-09-11
KR100996801B1 (ko)	2010-11-25
NZ560844A (en)	2008-08-29
EP1858552A2 (fr)	2007-11-28
BRPI0608815A2 (pt)	2010-01-26
LT2620450T (lt)	2019-02-11
US20080248047A1 (en)	2008-10-09
TW200719913A (en)	2007-06-01
US20090238820A1 (en)	2009-09-24
KR20070100848A (ko)	2007-10-11
AU2006220829A1 (en)	2006-09-14
EP1865986A2 (fr)	2007-12-19
LUC00312I2 (fr)	2025-02-03
CY2023018I1 (el)	2023-11-15
AR054233A1 (es)	2007-06-13
AU2006220828A1 (en)	2006-09-14
WO2006096490A3 (fr)	2006-12-28
BRPI0608855A2 (pt)	2010-02-02
HK1125297A1 (en)	2009-08-07
IL185483A (en)	2013-04-30
ES2707284T3 (es)	2019-04-03
JP2006249085A (ja)	2006-09-21
ES2569409T3 (es)	2016-05-10
HUS2300026I1 (hu)	2023-09-28
WO2006096491A9 (fr)	2008-04-03
JP6212509B2 (ja)	2017-10-11
NZ561137A (en)	2011-09-30
WO2006096461A3 (fr)	2006-12-21
AR053553A1 (es)	2007-05-09
US20090130119A1 (en)	2009-05-21
DK1865986T3 (en)	2016-04-11
PT2620450T (pt)	2018-12-17
IL225435A0 (en)	2013-06-27
KR20070100922A (ko)	2007-10-12
JP2006249084A (ja)	2006-09-21
TWI365747B (en)	2012-06-11
CA2600836A1 (fr)	2006-09-14
NL301240I2 (nl)	2025-07-31
JP2013032387A (ja)	2013-02-14
EP2620450B1 (fr)	2018-11-07
HUE028410T2 (en)	2016-12-28
TW200642694A (en)	2006-12-16
CY1121254T1 (el)	2020-05-29
AR062247A1 (es)	2008-10-29
BRPI0608815A8 (pt)	2017-03-21

Publication	Publication Date	Title
FR23C1029I2 (fr)	2024-06-14	Compositions d'anticorps anti-ctla-4
CY2021033I1 (el)	2022-03-24	Συνθεση αντισωματος ιντερλευκινης-13
FR21C1040I1 (fr)	2021-11-19	Formulations d'anticorps anti-cd20
MA29014B1 (fr)	2007-11-01	Formulations d'anticorps
EP1964852A4 (fr)	2010-02-24	Anticorps anti-ilt7
ATE464352T1 (de)	2010-04-15	Rheologiemodifizierte polyethylenzusammensetzungen
DK1771482T3 (da)	2014-10-20	HER2-antistofsammensætning
BRPI0511900A (pt)	2008-01-22	composições farmacêuticas
FR15C0048I2 (fr)	2015-11-20	Anticorps antagonistes de il-17
EP2109625A4 (fr)	2011-06-08	Utilisation de conjugues d'anticorps
ITMI20041252A1 (it)	2004-09-22	Composizioni perfluoroelastomeriche
EP1915177A4 (fr)	2011-08-31	Anticorps d'alpha-synucléine et techniques associées
EP1765396A4 (fr)	2008-07-02	Anticorps
ZA200707293B (en)	2009-04-29	Anti-CTLA-4 antibody compositions
EP1746141A4 (fr)	2010-04-07	Composition d' epaississement
DE602005016978D1 (de)	2009-11-12	Quecksilberfreisetzende Zusammensetzungen
DK1612200T3 (da)	2013-09-30	Gødningssammensætning
EP1967534A4 (fr)	2010-12-15	Composition d'adhésif
EP2004231A4 (fr)	2013-07-10	Conjugues d'un anticorps anti-tnf-alpha
EP1854467A4 (fr)	2011-11-16	Composition pour l'activation immunitaire
DE602005017191D1 (de)	2009-11-26	Geruchsreduzierte waschstück-zusammensetzung
EP1937814A4 (fr)	2010-05-05	Anticorps protéiques anti-apoptotiques
ITMI20041447A1 (it)	2004-10-20	Composizione farmaceutica comprendente gabapentina
ITMI20040943A1 (it)	2004-08-11	Composizione farmaceutica cicatrizzante
EP1712564A4 (fr)	2007-12-05	Anticorps monoclonal anti-nc1